{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-23-000031","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.731669+00:00","generated_at":"2026-06-16T02:14:13.504859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Myriad Genetics Q1 revenue $181.2M (+10% YoY); raises FY23 revenue guidance midpoint","bullets":["Q1 GAAP EPS $(0.67); adjusted EPS $(0.21); revenue $181.2M (+10% YoY).","Testing volumes +21% ex-SneakPeek; hereditary cancer +24%, GeneSight +31% YoY.","FY23 revenue guidance raised to $730-750M (previous $720-750M); gross margin 68-70% reaffirmed.","GAAP gross margin 67.3% (down 360bps YoY) due to product mix and $12.4M prior-year benefit.","Ended Q1 with $109.1M cash, no debt; management targets profitability by Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-23-000031","json":"https://secwatch.observer/filing/0000899923-23-000031.json","markdown":"https://secwatch.observer/filing/0000899923-23-000031.md","text":"https://secwatch.observer/filing/0000899923-23-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/0000899923-23-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/mygn-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:14:13.504859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c74a27a941d66226c06c12dc59fe82386c613a70","claim":"MYRIAD GENETICS INC reported the three months ended March 31, 2023 results: EPS $(0.67). Guidance raised.","evidence_excerpt":"Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/0000899923-23-000031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"EPS","value":"$(0.67)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}